Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 32

  • 1 201 clinical trials
  • 458 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia77Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Follicular lymphoma41Plasma cell myeloma refractory41Mantle cell lymphoma32Myelofibrosis31Chronic myeloid leukaemia29B-cell small lymphocytic lymphoma28Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17B-cell lymphoma refractory16B-cell type acute leukaemia16Paroxysmal nocturnal haemoglobinuria16Diffuse large B-cell lymphoma refractory14+340

Clinical trials in Blood and lymphatic system disorders

1 201 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 201 clinical trials

Haematological malignancy+1

Recruiting

Study on the Safety of CA-4948 and Ibrutinib for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Emavusertib
  • Sponsor:Curis Inc.

Plasma cell myeloma

Recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Castleman's disease

Recruiting

Study on Nintedanib for Adults with Unicentric Castleman Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nintedanib
  • Sponsor:Assistance Publique Hopitaux De Paris

Plasma cell myeloma+3

Recruiting

Long-Term Follow-Up Study for Patients with Myxoid/Round Cell Liposarcoma, Multiple Myeloma, Non-Small Cell Lung Cancer, or Synovial Sarcoma Treated with Letetresgene Autoleucel

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Letetresgene Autoleucel
  • Sponsor:USWM Ct LLC

Indolent systemic mastocytosis

Recruiting

Study of TL-895 for Patients with Relapsed or Refractory Myelofibrosis or Indolent Systemic Mastocytosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:1-4-{[6-Amino-5-(4-Phenoxy-Phenyl)-Pyrimidin-4-Ylamino]-Methyl}-4-Fluoro-Piperidin-1-Yl)-Propenone
  • Sponsor:Telios Pharma Inc.

Sickle cell anaemia+1

Recruiting

Study on the Effects of Exagamglogene Autotemcel for Patients with Transfusion-Dependent Beta-Thalassemia or Severe Sickle Cell Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Vertex Pharmaceuticals Inc.

Autoimmune haemolytic anaemia

Recruiting

Study on the Effectiveness of Apixaban and Enoxaparin Sodium in Preventing Blood Clots in Patients with Autoimmune Hemolytic Anemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Acute lymphocytic leukaemia

Recruiting

Study of Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Chronic lymphocytic leukaemia

Recruiting

Study of venetoclax, obinutuzumab and zanubrutinib combination therapy in young patients with high-risk Chronic Lymphocytic Leukemia and residual disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Allopurinol
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Factor VIII deficiency

Recruiting

Study on the Safety and Effects of NXT007 for Patients with Severe or Moderate Hemophilia A

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ro7589655
  • Sponsor:F. Hoffmann-La Roche AG

Acute lymphocytic leukaemia

Recruiting

Study on the Safety and Effects of AUTO1, Cyclophosphamide, and Fludarabine Phosphate in Children with Relapsed or Refractory B-cell Leukemia and Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Cyclophosphamide
  • Sponsor:Autolus Limited

Plasma cell myeloma

Recruiting

Study on Linvoseltamab and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Have Not Yet Received Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab122 clinical trialsVenetoclax114 clinical trialsCyclophosphamide100 clinical trialsLenalidomide98 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.